{
    "nctId": "NCT00204776",
    "briefTitle": "XELOX for Metastatic Breast Cancer",
    "officialTitle": "A Phase II Trial of Capecitabine and Oxaliplatin in Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "N/A",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Overall response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* preserved organ function\n* good performance status\n* no more than one prior therapy\n* no active brain metastasis\n\nExclusion Criteria:\n\n* No prior capecitabine or oxaliplatin\n* no con-current therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}